book excretion full 6 DEC 2021 (ebook)

ขอ 7.4.3.10 จากแนวทางการใหยา famciclovir (ขอมลู Clcr ผปู วย = 45 mL/min) สรปุ ดังน้ี Indication Dosing Modifications Dose in Patients Acute herpes zoster CrCl ≥60 mL/min: Regular dosage 500 mg q12hrs CrCl 40-59 mL/min: 500 mg q12hr CrCl 20-39 mL/min: 500 mg once daily CrCl <20 mL/min: 250 mg once daily Hemodialysis: 250 mg after each session Herpes labialis CrCl ≥60 mL/min: Regular dosage 500 mg q12hrs CrCl 40-59 mL/min: 750 mg once CrCl 20-39 mL/min: 500 mg once CrCl <20 mL/min: 250 mg once Hemodialysis: 250 mg once after dialysis Genital herpes CrCl ≥60 mL/min: Regular dosage 500 mg q12hrs (treatment of recurrent CrCl 40-59 mL/min: 500 mg q12hr disease) for 1 day (2 doses total) CrCl 20-39 mL/min: 500 mg once CrCl <20 mL/min: 250 mg once Hemodialysis: 250 mg once after dialysis Genital herpes CrCl ≥40 mL/min: Regular dosage Regular dosage = (suppressive therapy) CrCl 20-39 mL/min: 125 mg q12hr 250 mg PO q 12hrs CrCl <20 mL/min: 125 mg/day Hemodialysis: 125 mg after each session Herpes CrCl ≥40 mL/min: Regular dosage Regular dosage = Prevention of HSV reactivation: (HIV-infected adults) CrCl 20-39 mL/min: 500 mg/day 500 mg PO q 12hrs CrCl <20 mL/min: 250 mg/day Recurrent episodes: 500 mg PO Hemodialysis: 250 mg after each 48 hrs of symptom or lesion session onset ท่ีมา https://reference.medscape.com/drug/famvir-famciclovir-34261 147

ดชั นี คาํ หนา คาํ หนา A 1 Edema 6 Absorption 6, 17 ,44, 57 F Active transport Folic acid 9 AHFS drug information 6, 17 ,44, 57 Alprazolam 96 Flow llimited Atorvastatin 10, 13, 69 G 67 B 10, 69, 75 Gabapentin 4, 108 Biliary excretion Gastric emptying time Biotransformation 80 Glomerular filtration 40 Bowman's capsule 20 Glucuronide 14 C 14, 75 Capacity limited 39 Grapefruit Capacity limitted binding insensitive H 35 Capacity limitted binding insensitive 42 Carrier mediated transport 66 Half-life 59 Ceftriaxone 66 Henderson-Hassenbach 62 Chronopharmacokinetics 66 Hepatic artery 63 Chronotherapy 4 Hepatic clearance 59 Ciprofloxacin 40 Circadian effect 31, 33 ,111 Hepatic extraction ratio Clearance 102 Hepatocyte 81 Clonazepam 120 Hydrostatic pressure 98 Competition I Conjugation 31, 108, 111 Intestinal excretion 15 D 102 28 Diffusion 15 Distribution 20 Intracellular hydrostatic pressure 8 Drug information handbook 10 K 21 E 45 Ketoconazole 6 Elimination 14 Ketoprofen Elimination rate constant 9 Excretion L 6, 17, 44, 57 Exporter inhibitors 5 Lexicom online Extraction ratio 67 5 Loading dose 4, 108 98 Levothyroxine Lisinopril 15 Liothyronine 28 Losartan 15 Lithium 8M 21 Mamary excretion 148

คาํ หนา คํา หนา Medscape 100 R 23, 33 Metabolism 11 Renal clearance 96 Methotrexate 82, 84,113, 118 Rxlist drug information 47 Methylation 14 Ranitidine Micromedex 98 S 7 Modified diet in renal disease (MDRD) 88 Sodium iodide transporter 81 N Salivary excretion 44 Naproxen 18 Saturation 59 Nortriptyline 13 Sinusoid 84 O Sweat excretion 10, 13, 69-70, 72, 75 Organ clearance 21 Simvastatin 14 Osmotic pressure 41 Sulfation Obese 7 T 5, 17, 84 Occular permeability 118 Tetracycline 21, 23, 50 P Totalbody clearance Passive transport 4 Tubular reabsorption 41, 50 Pore transport 4 Tubular secretion 44, 51 Periportal Hepatocyte 61 Tramadol 7, 69-70, 74 Perivenous 61 V Pharmacodynamics 1 Verapamil 8, 13-14, 64, 69 Pharmacokinetics 1 Valproic acid 64, 82, 105, 112, 119 Phase 1 metabolism 11 W Phase 2 metabolism 11 Warfarin 5, 10, 13, 64, 68 Portal vein 59 X Protein binding 42 Xanax 69 Permeability 6, 108 Z Q zolpedem 69 Quaternary ammonium 47, 81 Quinidine 8, 13-14, 64 68-69, 75, 82 Quinine 13, 43, 75, 81, 106 149

ประวตั ผิ เู ขยี น ชื่อ-นามสกุล กรณั ฑรตั น ทิวถนอม ตาํ แหนง ผชู วยศาสตราจารย ดร. สถานท่ที ํางาน คณะเภสัชศาสตร มหาวทิ ยาลยั ศิลปากร การศึกษา ภด. (บรบิ าลทางเภสชั กรรม) จฬุ าลงกรณ มหาวิทยาลัย (2551) ภม. (เภสชั กรรมคลินิก) มหาวิทยาลัยมหิดล (2545) ภบ. มหาวิทยาลัยศลิ ปากร (2538) Scholarship and Grant 1. The University Developing Commission (UDC) Programme 1995-1998 2. Research grant from Government Pharmaceutical Organization 1996 3. The training grant for Therapeutic Drug Mornitoring from the embassy of France 1999 4. The Faculty scholarship for participating European Society of Clinical Pharmacy conference at Malta 2001. 5. The Faculty scholarship for PhD 2002-2003, at present 6. The CRN Schlolarship for PhD. 2003-2005 7. ISN travel grant 2005 8. Faculty research grant (2010) 9. University research grant (2011) 150

10. ISPOR Travel grant (2012) 11. NRCT research grant (2016) 12. Graduate research grant (2017) 13. Faculty research grant (2021) Publications 1. Tewthanom K. The Effect of Kahoot Web-Based Learning on Learning Skills of Pharmacy Students:The Trend in Clinical Pharmacokinetics Course for 2 Generations. Indian J of Pharmaceutical Education and Research. 2019;53(2):212-5. 2. Karunrat Tewthanom, Chanudom Cherachat, Chudaporn Sukkasem, Chosita Somwangprasert, Suchima Pornbunjerd, Napa Parinyanitikul. (2018) Factor associated transtuzumab cardiotoxicity in breast cancer: a case control study. In proceeding of Unity in Diversity and the Standardization of Clinical Pharmacy Services: Proceedings of the 17th Asian Conference on Clinical Pharmacy (ACCP 2017), July 28-30, 2017, Yogyakarta, Indonesia, edited by Elida Zairina, ISBN 9781138081727. 3. Karunrat Tewthanom, Chanudom Cherachat, Chudaporn Sukkasem, Chosita Somwangprasert, Suchima Pornbunjerd. Breast cancer therapy and cardiotoxicity of Trastuzumab in Breast cancer patients. Veridian E-Journal, Science and Technology Silpakorn University. 2017:4(2) March – April; 1-18.. 4. Karunrat Tewthanom. Sofosbuvir: current information for hepatitis C treatment. Thai Bull Pharm Sci. 2017; 12(1):91-107. 5. Wikawee Russameethum, Karunrat Tewthanom. Risk-benefit of high dose metformin beyond current evidence-based pharmacotherapy. Thai Bull Pharm Sci. 2017; 12(1):55-62. 6. Tewthanom K, Jongjaroenprasert W. The pharmacokinetics of 2 doses (50 mcg and 100 mcg) levothyroxine treatment in athyreotic patients. International Journal of Applied Pharmaceutics. 2016:8(4); 66-68. 6. Karunrat Tewthanom, Rinsook Ongarjsakulman, Theerarat Tankhum Lithuim Serum Level In Children; The tool for dose adjustment is needed? : Preliminary data at Yuwaprasart Waithayopathum Child Psychiatric Hospital. 26th FAPA congress 2016. 9-13 November 2016. Bangkok, Thailand 7. Karunrat Tewthanom, Experiential Learning Model in Pharmacy Orientation Course: the preliminary development activities for future trends of 21st Century of Pharmacy Education. International of Pharmacy Education and Research 2016:3(3); 1-4. 8. Tewthanom K. “The screening of skin carotenoid concentration (SCC) in patients with cardiovascular disease and Diabetes Mellitus: An association assessmentin single study.” 151

In Proceeding of 14th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology 2015. Rotterdam, Netherland, October 11-15, 2015. 9. Tewthanom K. “Cost Effectiveness Analysis among Patients with Diabetes Mellitus or Cardiovascular Diseases receiving second-line treatment with intensive dose of Simvastatin Atorvastatin and Atorvastatin-Ezetimibe combination in General Practice” In Proceeding of ISPOR 20th Annual International meeting, Philadelphia, USA, May 16-20, 2015. 10. Tewthanom K. “Cost Effectiveness Analysis of Simvastatin Atorvastatin and Atorvastatin- Ezetimibe combination among Patients with Diabetes Mellitus or Cardiovascular Diseases in General Practice.” In Proceeding of ISPOR 20th Annual International meeting, Philadelphia, USA, May 16-20, 2015. 11. Tewthanom K, Rattanakunooprakarn H. Factor affecting the assessment of the cost effectiveness of statins in the primary prevention of coronary heart disease. Journal of TBPS 2014; 9,1: 38-56. 12. Duangmee K, Phetsai C, Khunthongphet U, Sengsoon N, Tewthanom K. Study of relationship between trigger tools and adverse drug event at Somdet Phra Sangharaja the 19 th hospital, Kanchanaburi. Conference: The 25th FAPA Congress 2014 in Malaysian Journal of Pharmacy, At Kotakinabalu Malaysia, Malaysian Journal Volume: 1 13. Tewthanom K, Chaiwirattana N, Saelim W et al. Hypertensive medication discrepancies at the time of hospital admission: the initiative problem’s survey process in community hospital setting. J Pharm Biomed Sci. 2013; 26:406-09. 152